The European Medicines Agency has begun reviewing a new batch of treatments for potential pan-EU marketing authorization, including parsaclisib, a next-generation PI3K-delta inhibitor, and a topical gel formulation of the generic drug sirolimus, both of which have orphan status.
Parsaclisib, from Incyte, was filed with the EMA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL)